INS and type 2 diabetes mellitus: Taken together, these mechanisms of action, plus the amplification effect on glucose-dependent insulin secretion and suppression of glucagon release, have raised the possibility of a substantial improvement in islet cell function over time in patients with T2DM managed with incretin-based therapies.